Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling

R Gieschke1, B G Reigner, J L Steimer

  • 1Pharma Development, F. Hoffmann-La Roche, Basel, Switzerland.

International Journal of Clinical Pharmacology and Therapeutics
|November 14, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.

CPT: pharmacometrics & systems pharmacology·2016
Same author

Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI.

CPT: pharmacometrics & systems pharmacology·2013
Same author

Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.

Clinical pharmacology and therapeutics·2011
Same author

Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers.

Journal of psychopharmacology (Oxford, England)·2011
Same author

Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.

International journal of clinical pharmacology and therapeutics·2006
Same author

Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis.

Current drug metabolism·2006

Computer simulations, using pharmacokinetic and pharmacodynamic models, can predict clinical trial outcomes for drugs. This approach enhances the evaluation of drug safety and efficacy, optimizing development.

Area of Science:

  • Pharmacometrics
  • Clinical Pharmacology
  • Computational Biology

Background:

  • Computer simulations are widely used in engineering for efficient product development.
  • Recently, simulations have been proposed to support clinical drug development by predicting trial outcomes.
  • Pharmacokinetic (PK) and pharmacodynamic (PD) models combined with Monte Carlo methods form the basis for clinical trial simulation.

Purpose of the Study:

  • To introduce the fundamental concepts of clinical trial simulation.
  • To illustrate the application of simulation in drug development using an oral anticancer drug example.
  • To demonstrate how simulations can assess the impact of design features on drug safety and efficacy evaluations.

Main Methods:

  • Utilizing pharmacokinetic and pharmacodynamic mathematical models.

Related Experiment Videos

  • Employing Monte Carlo simulation techniques.
  • Applying simulations to an oral anticancer drug development scenario.

    • Main Results:

    • Computer simulations effectively predict clinical outcomes for planned trials.
    • Simulations allow for the evaluation of design features' impact on safety and efficacy assessments.
    • These impacts are often difficult to ascertain through traditional methods.

    Conclusions:

    • Clinical trial simulation is a valuable tool for optimizing drug development processes.
    • The methodology provides insights into drug safety and efficacy not easily obtainable otherwise.
    • Resources for simulation training and software are available to support this approach.